Jun 20, 2025
Cirius Therapeutics Announces Positive Data for MPC Inhibitor 0602K Alone and in Combination with Tirzepatide
Jun 04, 2025
0602K + Tirzepatide Muscle Mass / Function and Adipose Transformation Data to be Presented at ADA Scientific Sessions
Mar 25, 2025
Cirius Therapeutics to Present at Upcoming Healthcare Conferences
Jun 15, 2020
Data Presented at the 2020 ADA Scientific Sessions Show that Patients Treated with Cirius Therapeutics' MSDC-0602K Showed Improved Insulin Handling
Oct 21, 2019
Cirius Therapeutics' Phase 2b Data of MSDC-0602K for the Treatment of NASH Accepted as a Late-Breaking Oral Presentation at The Liver Meeting
Jun 12, 2019
Cirius Therapeutics Expands Scientific Advisory Board
Jun 05, 2019
Interim Data on Cirius Therapeutics' MSDC-0602K to be Presented at the American Diabetes Association Scientific Sessions
Jun 03, 2019
Cirius Therapeutics Adds to Leadership Team
Apr 12, 2019
Cirius Therapeutics Announces Presentation of Interim Data from Phase 2b Clinical Study of MSDC-0602K at The International Liver Congress 2019
Mar 27, 2019
Cirius Therapeutics to Present Preclinical Data for Lead Drug Candidate in NASH at The International Liver Congress
Dec 13, 2018
Cirius Therapeutics Expands Board of Directors with Appointment of Elaine D. Sun
Nov 06, 2018
Cirius Therapeutics Announces Two Posters on MSDC-0602K to be Presented at The Liver Meeting 2018
May 02, 2018
Cirius Therapeutics Reaches Enrollment Target in Phase 2b EMMINENCE Trial in NASH
Apr 12, 2018
Cirius Therapeutics' Preclinical Data Demonstrates Potential for Lead Drug Candidate MSDC-0602K in NASH
Mar 29, 2018
Cirius Therapeutics to Present Late-Breaking Poster at The International Liver Congress
Jan 04, 2018
Cirius Therapeutics Expands Board of Directors with Appointment of Dennis M. Fenton
Oct 20, 2017
Cirius Therapeutics to Present Poster at The Liver Meeting 2017